Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 14/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001502 | 0.96 | MME (0.37) | TSHRMME | |
| SCHEMBL4001628 | 0.94 | MME (0.36) | TSHRMME | |
| SCHEMBL3999986 | 0.92 | CHRM1 (0.33) | MMECHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL3996209 | 0.81 | CHRM1 (0.33) | TSHRNFKB1CYP2C19MMECHRM1 | |
| SCHEMBL3995230 | 0.78 | MME (0.35) | MMECHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL3994883 | 0.78 | MME (0.35) | TSHRMMECHRM1AKR1A1CHRM3 | |
| SCHEMBL3994181 | 0.77 | MME (0.35) | TSHRMMECHRM1AKR1A1CHRM3 | |
| SCHEMBL18762455 | 0.76 | GRM1 (0.44) | TSHRNFKB1CYP2C19GRIK1GRIK2 | |
| SCHEMBL18762540 | 0.76 | GRM1 (0.44) | TSHRNFKB1CYP2C19GRIK1GRIK2 | |
| SCHEMBL18775023 | 0.76 | GRM1 (0.44) | TSHRNFKB1CYP2C19GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | claimed |
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | TSHR 3218/4885NFKB1 3315/4885CYP2C19 4006/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | TSHR 3493/4885NFKB1 1751/4885CYP2C19 4428/4885 |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | TSHR 3120/4885NFKB1 2109/4885CYP2C19 3292/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | TSHR 2948/4885NFKB1 1879/4885CYP2C19 3299/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | TSHR 3218/4885NFKB1 3315/4885CYP2C19 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.